Abstract
Aims
This study aimed to evaluate the effect of pioglitazone on brown adipose tissue function and hypothalamic gliosis in humans. Brown adipose tissue and the hypothalamus are regarded as important potential pharmacological targets to metabolic diseases, and defining the impact of current therapies on their structure and/or function could provide therapeutic advance in this field.
Methods
Six patients with type 2 diabetes were treated for 24 weeks with pioglitazone 30 mg/day as an add-on therapy. Brown adipose tissue glucose uptake and volume were determined using 18F-FDG PET/CT scans; hypothalamic gliosis was determined using MRI scans; blood was collected for hormone and biochemistry measurements. All tests were performed at inclusion and six months after pioglitazone introduction.
Results
Pioglitazone treatment led to a significant 3% body mass increase. There were neither changes in cold-induced brown adipose tissue glucose uptake and volume nor changes in hypothalamic gliosis.
Conclusions
This is a proof-of-concept study that provides clinical evidence for a lack of action of a thiazolidinedione, pioglitazone, to promote homogeneous and measurable changes in brown adipose tissue volume and also in hypothalamic gliosis after 6 months of treatment.
Similar content being viewed by others
References
Stanford KI, Middelbeek RJ, Townsend KL et al (2013) Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 123(1):215–223
Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84(1):277–359
Chen KY, Cypess AM, Laughlin MR et al (2016) Brown adipose reporting criteria in Imaging STudies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans. Cell Metab 24(2):210–222
de-Lima-Júnior JC, Souza GF, Moura-Assis A et al (2019) Abnormal brown adipose tissue mitochondrial structure and function in IL10 deficiency. EBioMedicine 39:436–447
Rodovalho S, Rachid B, De-Lima-Junior JC et al (2017) Impairment of body mass reduction-associated activation of brown/beige adipose tissue in patients with type 2 diabetes mellitus. Int J Obes (Lond). 41(11):1662–1668
Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52(10):2169–2181
Association AD (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80
Tahari AK, Chien D, Azadi JR, Wahl RL (2014) Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 55(9):1481–1484
Sewaybricker LE, Schur EA, Melhorn SJ et al (2019) Initial evidence for hypothalamic gliosis in children with obesity by quantitative T2 MRI and implications for blood oxygen-level dependent response to glucose ingestion. Pediatr Obes. 14(2):e12486
Landecho MF, Colina I, Sunsundegui P, Camarero B, Núñez-Córdoba JM, Beloqui Ó (2019) Comparison of correlations of equation-derived body fat percentage and body mass index with carotid intima-media thickness. Acta Diabetol 56(3):373–375
Wang S, Wang Z, Chen C et al (2019) Contribution of epicardial and abdominopelvic visceral adipose tissues in Chinese adults with impaired glucose regulation and diabetes. Acta Diabetol 56(9):1061–1071
Higgins PB, Folli F, Andrade MCR et al (2019) Duodenal adipose tissue is associated with obesity in baboons (Papio sp): a novel site of ectopic fat deposition in non-human primates. Acta Diabetol 56(2):227–236
Moreno-Galdós L, Barba-Cosials J, Núñez-Córdoba JM (2018) Association between echocardiographic epicardial adipose tissue and E/e′ ratio in obese adults. Acta Diabetol 55(1):103–106
Loh RKC, Formosa MF, Eikelis N et al (2018) Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans. Diabetologia 61(1):220–230
Festuccia WT, Blanchard PG, Richard D, Deshaies Y (2010) Basal adrenergic tone is required for maximal stimulation of rat brown adipose tissue UCP1 expression by chronic PPAR-gamma activation. Am J Physiol Regul Integr Comp Physiol 299(1):R159–R167
Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H (1987) Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes 36(1):6–13
Lefebvre AM, Laville M, Vega N et al (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47(1):98–103
Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56(10):2153–2163
Armato JP, DeFronzo RA, Abdul-Ghani M, Ruby RJ (2018) Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 6(10):781–789
Hanssen MJ, Hoeks J, Brans B et al (2015) Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. Nat Med 21(8):863–865
Diano S, Liu ZW, Jeong JK et al (2011) Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med 17(9):1121–1127
Rachid B, van de Sande-Lee S, Rodovalho S et al (2015) Distinct regulation of hypothalamic and brown/beige adipose tissue activities in human obesity. Int J Obes (Lond). 39(10):1515–1522
Thaler JP, Yi CX, Schur EA et al (2012) Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 122(1):153–162
van de Sande-Lee S, Melhorn SJ, Rachid B et al (2019) Radiologic evidence that hypothalamic gliosis is improved after bariatric surgery in obese women with type 2 diabetes. Int J Obes (Lond). https://doi.org/10.1038/s41366-019-0399-8
Funding
This research was sponsored by GSK (GlaxoSmithKline plc). This research was also supported by the São Paulo Research Foundation (FAPESP 2013/076078).
Author information
Authors and Affiliations
Contributions
JCLJ drafted the first version of the manuscript. JCLJ, FF and LV wrote the manuscript. JCLJ, FF and LV edited and reviewed the manuscript. JCLJ, RMC and MMP performed the statistical analyses, reviewed/edited the manuscript and researched the data. JCLJ and MMP performed PET/CT analysis. CDR performed PET/CT scanning. FC performed MRI scanning and edited partially the manuscript. SVSL performed MRI analysis. LV, SR and BR conceived the design of the study. JCLJ, SR and BR recruited and assisted the patients.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standard
The study was approved by the local medical ethical committee of the University of Campinas (Ethics Committee approval CAAE: 32930314.8.0000.5404).
Informed consent
All patients being enrolled into this registry provided written informed consent.
Additional information
Managed By Massimo Federici.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
de-Lima-Júnior, J.C., Rodovalho, S., Van de Sande-Lee, S. et al. Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. Acta Diabetol 56, 1333–1339 (2019). https://doi.org/10.1007/s00592-019-01418-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01418-2